Antibody Therapies Vs. Omicron: Vir Stands Up But Regeneron And Lilly Fail

Regeneron Pledges Update By Early 2022

 
• By Andrew McConaghie
Covid testing lab
The results suggest the most widely used antibody therapies are be 'inactive' against Omicron. • Source: Alamy

More from Clinical Trials

More from R&D